emavusertib + ibrutinib

This combination therapy consists of **emavusertib** (CA-4948), an oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (**IRAK4**) and **FLT3**, and **ibrutinib**, an oral small molecule inhibitor of Bruton tyrosine kinase (**BTK**). The combination is under investigation for the treatment of **relapsed/refractory primary central nervous system lymphoma** (R/R PCNSL) and other B-cell malignancies, especially those resistant to BTK inhibitors. Emavusertib targets the TLR/IL-1R signaling pathway, critical for B cell proliferation and survival, while ibrutinib inhibits the B-cell receptor (BCR) pathway. Preclinical and early clinical results indicate that dual inhibition of IRAK4 and BTK can overcome resistance to BTK inhibition alone, showing promising efficacy and a tolerable safety profile in difficult-to-treat hematologic malignancies[1][2][3][5].

Other names

ibrutinib + emavusertibCA-4948 + ibrutinib